center	assay	assay-info	cell-lines	cell-lines-meta	purturbagens	perturbagens-meta	perturbagens-meta (cont)	perturbagens-meta (cont)	signatures-meta	map	readouts	readout-count	data release date	data release date	data release date	data release date	data release date3	release level3	data release date4	release level4			"name1,type1(normal or ips-differentiated),class1(normal,cancer line,):control-or-disease,tissue1;name2,type2,class2,tissue2"	"count,type (OR) count1,type1;count2,type2"	"name1,type1,perturbagens1;name2,type2, purturbagens2"	"pair:type1,count1;type2,count2"	"dose1,dose2;dose-count"	"time1(,time2,time3);time-unit;time-points"	"reps,techReps"	"pert1,cell-line1;pert2,cell-line2"	name1:datatype1;name2:datatype2		LEVEL 1	LEVEL 2	LEVEL 3	LEVEL 4	THIRD DATE IF GIVEN	levels of THIRD DATE	FOURTH DATE IF GIVEN	levels of FOURTH DATE										one-all = each pert to all cell lines										ISMMS - Iyengar	RSeq	Cardiotoxicity Signatures	"Promocell myocytes line 1,normal,normal,heart;Promocell myocytes line 2,normal,normal,heart;Promocell myocytes line 3,normal,normal,heart"	"3,normal"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,30"	;1	48;hrs;1	3	one-all	DEGs:gene list		2015 4 30	2015 4 30	2015 4 30	2015 4 30				ISMMS - Iyengar	Proteomics	Cardiotoxicity Signatures	"Promocell myocytes line 1,normal,normal,heart;Promocell myocytes line 2,normal,normal,heart;Promocell myocytes line 3,normal,normal,heart"	"3,normal"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,10"	;1	48;hrs;1	3	one-all	DEPs:protein list		2015 4 30	2015 4 30	2015 4 30	2015 4 30				ISMMS - Iyengar	Western blots/PCR (validation assays)	Cardiotoxicity Signatures	"Promocell myocytes line 1,normal,normal,heart;Promocell myocytes line 2,normal,normal,heart;Promocell myocytes line 3,normal,normal,heart"	"3,normal"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,15"	;1	48;hrs;1	3	one-all	image:image		2015 4 30	2015 4 30	2015 4 30	2015 4 30				ISMMS - Iyengar	RSeq	Cardiotoxicity Signatures	"Promocell myocytes line 4,normal,normal,heart;Myocytes derived from NeuroLINCS iPSCs line 1,ips-differentiated,normal,heart;Myocytes derived from NeuroLINCS iPSCs line 2,ips-differentiated,normal,heart"	"1,normal;2,ips-differentiated"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,30"	;1	48;hrs;1	3	one-all	DEGs:gene list		2015 7 31	2015 7 31	2015 7 31	2015 7 31				ISMMS - Iyengar	Proteomics	Cardiotoxicity Signatures	"Promocell myocytes line 4,normal,normal,heart;Myocytes derived from NeuroLINCS iPSCs line 1,ips-differentiated,normal,heart;Myocytes derived from NeuroLINCS iPSCs line 2,ips-differentiated,normal,heart"	"1,normal;2,ips-differentiated"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,10"	;1	48;hrs;1	3	one-all	DEPs:protein list		2015 7 31	2015 7 31	2015 7 31	2015 7 31				ISMMS - Iyengar	Western blots/PCR (validation assays)	Cardiotoxicity Signatures	"Promocell myocytes line 4,normal,normal,heart;Myocytes derived from NeuroLINCS iPSCs line 1,ips-differentiated,normal,heart;Myocytes derived from NeuroLINCS iPSCs line 2,ips-differentiated,normal,heart"	"1,normal;2,ips-differentiated"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,15"	;1	48;hrs;1	3	one-all	image:image		2015 7 31	2015 7 31	2015 7 31	2015 7 31				ISMMS - Iyengar	RSeq	Cardiotoxicity Signatures	"Mount Sinai iPSC-derived myocytes line 1,ips-differentiated,normal,heart;Mount Sinai iPSC-derived myocytes line 2,ips-differentiated,normal,heart"	"2,ips-differentiated"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,30"	;1	48;hrs;1	3	one-all	DEGs:gene list		2015 10 15	2015 10 15	2015 10 15	2015 10 15				ISMMS - Iyengar	Proteomics	Cardiotoxicity Signatures	"Mount Sinai iPSC-derived myocytes line 1,ips-differentiated,normal,heart;Mount Sinai iPSC-derived myocytes line 2,ips-differentiated,normal,heart"	"2,ips-differentiated"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,10"	;1	48;hrs;1	3	one-all	DEPs:protein list		2015 10 15	2015 10 15	2015 10 15	2015 10 15				ISMMS - Iyengar	Western blots/PCR (validation assays)	Cardiotoxicity Signatures	"Mount Sinai iPSC-derived myocytes line 1,ips-differentiated,normal,heart;Mount Sinai iPSC-derived myocytes line 2,ips-differentiated,normal,heart"	"2,ips-differentiated"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,15"	;1	48;hrs;1	3	one-all	image:image		2015 10 15	2015 10 15	2015 10 15	2015 10 15				ISMMS - Iyengar	RSeq	"Cardiomyocyte ""Efficacy/Toxicity Ratio"" Joint project- Collaborators: ISMMS, UCI, HMS, Broad/Golub, Broad/Jaffe, OHSU & DCIC*"	 Which four? Birtwistle unsure of structure	"4,normal"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,6"	;1	48;hrs;1	"3,3"	one-all	DEGs:gene list		2015 10 15	2015 10 15	2015 10 15	2015 10 15				ISMMS - Iyengar	Proteomics	"Cardiomyocyte ""Efficacy/Toxicity Ratio"" Joint project- Collaborators: ISMMS, UCI, HMS, Broad/Golub, Broad/Jaffe, OHSU & DCIC*"	 Which four? Birtwistle unsure of structure	"4,normal"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,6"	;1	48;hrs;1	"3,3"	one-all	DEPs:protein list		2015 10 15	2015 10 15	2015 10 15	2015 10 15				ISMMS - Iyengar	Western blots/PCR (validation assays)	"Cardiomyocyte ""Efficacy/Toxicity Ratio"" Joint project- Collaborators: ISMMS, UCI, HMS, Broad/Golub, Broad/Jaffe, OHSU & DCIC*"	 Which four? Birtwistle unsure of structure	"4,normal"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,15"	;1	48;hrs;1	"3,3"	one-all	image:image		2015 10 15	2015 10 15	2015 10 15	2015 10 15				ISMMS - Iyengar	RSeq	Cardiotoxicity Signatures	"Mount Sinai iPSC-derived myocytes line 3,ips-differentiated,normal,heart;Mount Sinai iPSC-derived myocytes line 4,ips-differentiated,normal,heart"	"2,ips-differentiated"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,30"	;1	48;hrs;1	3	one-all	DEGs:gene list		2016 1 31	2016 1 31	2016 1 31	2016 1 31				ISMMS - Iyengar	Proteomics	Cardiotoxicity Signatures	"Mount Sinai iPSC-derived myocytes line 3,ips-differentiated,normal,heart;Mount Sinai iPSC-derived myocytes line 4,ips-differentiated,normal,heart"	"2,ips-differentiated"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,10"	;1	48;hrs;1	3	one-all	DEPs:protein list		2016 1 31	2016 1 31	2016 1 31	2016 1 31				ISMMS - Iyengar	Western blots	Cardiotoxicity Signatures	"Mount Sinai iPSC-derived myocytes line 3,ips-differentiated,normal,heart;Mount Sinai iPSC-derived myocytes line 4,ips-differentiated,normal,heart"	"2,ips-differentiated"	"Afatinib,FDA approved drug;Axitinib,FDA approved drug;Bosutinib,FDA approved drug;Cabozantinib,FDA approved drug;Ceritinib,FDA approved drug;Crizotinib,FDA approved drug;Dabrafenib,FDA approved drug;Dasatinib,FDA approved drug;Erlotinib,FDA approved drug;Gefitinib,FDA approved drug;Imatinib,FDA approved drug;Lapatinib,FDA approved drug;Nilotinib,FDA approved drug;Pazopanib,FDA approved drug;Ponatinib,FDA approved drug;Regorafenib,FDA approved drug;Ruxolitinib,FDA approved drug;Sorafenib,FDA approved drug;Sunitinib,FDA approved drug;Tofacitinib,FDA approved drug;Trametinib,FDA approved drug;Vandetanib,FDA approved drug;Vemurafenib,FDA approved drug;Trastuzumab,FDA approved drug;Trastuzumab + Ursodeoxycholic acid,FDA approved drug;Trastuzumab + Loperamide,FDA approved drug;Trastuzumab + Domperidone,FDA approved drug;Sunitinib + Ursodeoxycholic acid,FDA approved drug;Sunitinib + Domperidone,FDA approved drug;Sunitinib + Loparemide,FDA approved drug;Sunitinib + Prednisolone,FDA approved drug;Sorafenib + Ursodeoxycholic acid,FDA approved drug;Sorafenib + Entecavir,FDA approved drug;Sorafenib + Diethylpropion,FDA approved drug;Sorafenib + Olmesartan,FDA approved drug;Sorefenib + Diclofenac,FDA approved drug;Dasatinib + Cytarabine,FDA approved drug;Erlotinib + Cefuroxime,FDA approved drug;Imatinib + Cyclosporine,FDA approved drug;Ursodeoxycholic acid,FDA approved drug;Loperamide,FDA approved drug;Domperidone,FDA approved drug;Prednisolone,FDA approved drug;Entecavir,FDA approved drug;Diethylpropion,FDA approved drug;Olmesartan,FDA approved drug;Diclofenac,FDA approved drug;Cytarabine,FDA approved drug;Cefuroxime,FDA approved drug;Cyclosporine,FDA approved drug"	"false:FDA approved drugs,3"	;1	48;hrs;1	3	one-all	image:image		2016 1 31	2016 1 31	2016 1 31	2016 1 31																								Broad - Golub	evaluating shRs (vs CRISPRs)	L1000	"MCF7,normal,cancer line,breast;PC3,normal,cancer line,prostate;A375,normal,cancer line,skin;HT29,normal,cancer line,ovarian;HA1E,normal,imm cells,colon;A549,normal,cancer line,lung"	"2.5,normal"	"EGFP(control),genetic,12 (6 sgRs and 6 shRs);EGFR,genetic,12 (6 sgRs and 6 shRs);MUC1,genetic,12 (6 sgRs and 6 shRs);BRAF,genetic,12 (6 sgRs and 6 shRs);MTOR,genetic,12 (6 sgRs and 6 shRs);AKT2,genetic,12 (6 sgRs and 6 shRs);AURKB,genetic,12 (6 sgRs and 6 shRs);BIRC5,genetic,12 (6 sgRs and 6 shRs);MCL1,genetic,12 (6 sgRs and 6 shRs);MYL9,genetic,12 (6 sgRs and 6 shRs);ERBB3,genetic,12 (6 sgRs and 6 shRs);ERG,genetic,12 (6 sgRs and 6 shRs);PDGFA,genetic,12 (6 sgRs and 6 shRs);PIK3CA,genetic,12 (6 sgRs and 6 shRs);CXCR4,genetic,12 (6 sgRs and 6 shRs);KIT,genetic,12 (6 sgRs and 6 shRs);KRAS,genetic,12 (6 sgRs and 6 shRs)"	"false:genetic,900"	;1	;;1	3	one-all	L1000 gene expressions:number		2015 6 30	2015 6 30	2015 6 30	2015 6 30				Broad - Golub	evaluating CRISPRs (vs shRs)	L1000	"MCF7,normal,cancer line,breast;PC3,normal,cancer line,prostate;A375,normal,cancer line,skin;HT29,normal,cancer line,ovarian;HA1E,normal,imm cells,colon;A549,normal,cancer line,lung"	"2.5,normal"	"EGFP(control),genetic,12 (6 sgRs and 6 shRs);EGFR,genetic,12 (6 sgRs and 6 shRs);MUC1,genetic,12 (6 sgRs and 6 shRs);BRAF,genetic,12 (6 sgRs and 6 shRs);MTOR,genetic,12 (6 sgRs and 6 shRs);AKT2,genetic,12 (6 sgRs and 6 shRs);AURKB,genetic,12 (6 sgRs and 6 shRs);BIRC5,genetic,12 (6 sgRs and 6 shRs);MCL1,genetic,12 (6 sgRs and 6 shRs);MYL9,genetic,12 (6 sgRs and 6 shRs);ERBB3,genetic,12 (6 sgRs and 6 shRs);ERG,genetic,12 (6 sgRs and 6 shRs);PDGFA,genetic,12 (6 sgRs and 6 shRs);PIK3CA,genetic,12 (6 sgRs and 6 shRs);CXCR4,genetic,12 (6 sgRs and 6 shRs);KIT,genetic,12 (6 sgRs and 6 shRs);KRAS,genetic,12 (6 sgRs and 6 shRs)"	"false:genetic,800"	;1	;;1	3	one-all	L1000 gene expressions:number		2015 6 30	2015 6 30	2015 6 30	2015 6 30				Broad - Golub	deep exploration of cellular context (small-molecules)	L1000	"MCF7,normal,cancer line,breast;PC3,normal,cancer line,prostate;A375,normal,cancer line,skin;HT29,normal,cancer line,ovarian;HA1E,normal,imm cells,colon;A549,normal,cancer line,lung;HPAC,normal,cancer line,pancreas"	"2.5,normal"	"acetyldinaline (Ci-994),chemical;alpha-estradiol,chemical;belinostat,chemical;beta-estradiol,chemical;BIX 01294,chemical;BIX 01338,chemical;CPI-169,chemical;decitabine,chemical;DMSO,chemical;entinostat,chemical (MS275),chemical;fluphenazine,chemical;fulvestrant,chemical;geldanamycin,chemical;genistein,chemical;GSK-J4,chemical;GSK1210151A,chemical;gsk126,chemical;GSK525762A,chemical;jq1,chemical;LY-294002,chemical;methylstat,chemical;Mitoxantrone,chemical;monorden,chemical;OSI-027,chemical;rapamycin,chemical;resveratrol,chemical;salermide,chemical;sirolimus,chemical;staurosporine,chemical;tanespamycin,chemical;thioridazine,chemical;tretinoin (atra),chemical;trichostatin a,chemical;trifluoperazine,chemical;troglitazone,chemical;unc0321,chemical;unc0646,chemical;unc1215,chemical;valproic acid,chemical;vorinostat,chemical;withaferin a,chemical;wortmannin,chemical;zebularine,chemical"	"false:chemical,360"	;6	;;1	3	one-all	L1000 gene expressions:number		2015 6 30	2015 6 30	2015 6 30	2015 6 30				Broad - Golub	deep exploration of cellular context (biologicals)	L1000	"MCF7,normal,cancer line,breast;PC3,normal,cancer line,prostate;A375,normal,cancer line,skin;HT29,normal,cancer line,ovarian;HA1E,normal,imm cells,colon;A549,normal,cancer line,lung;HPAC,normal,cancer line,pancreas"	"12.5,normal"	"acetyldinaline (Ci-994),chemical;alpha-estradiol,chemical;belinostat,chemical;beta-estradiol,chemical;BIX 01294,chemical;BIX 01338,chemical;CPI-169,chemical;decitabine,chemical;DMSO,chemical;entinostat,chemical (MS275),chemical;fluphenazine,chemical;fulvestrant,chemical;geldanamycin,chemical;genistein,chemical;GSK-J4,chemical;GSK1210151A,chemical;gsk126,chemical;GSK525762A,chemical;jq1,chemical;LY-294002,chemical;methylstat,chemical;Mitoxantrone,chemical;monorden,chemical;OSI-027,chemical;rapamycin,chemical;resveratrol,chemical;salermide,chemical;sirolimus,chemical;staurosporine,chemical;tanespamycin,chemical;thioridazine,chemical;tretinoin (atra),chemical;trichostatin a,chemical;trifluoperazine,chemical;troglitazone,chemical;unc0321,chemical;unc0646,chemical;unc1215,chemical;valproic acid,chemical;vorinostat,chemical;withaferin a,chemical;wortmannin,chemical;zebularine,chemical"	"false:chemical,50"	;6	;;1	3	one-all	L1000 gene expressions:number		2015 6 30	2015 6 30	2015 6 30	2015 6 30																								HMS - Sorger	20215: Sensitivity measures of MDA-MB-231 and HME-1 cell lines to LINCS Phase I TransCenter Project kinase inhibitors--single drug treatments	"Imaging assay--monitoring cell number via Hoechst 33342 (nuclei) staining. To generate measures of the sensitivities of two cell lines to LINCS Phase I TransCenter Project kinase inhibitors we treated cells with single drugs at multiple concentrations.  After 3 days of incubation, cells were stained with Hoechst 33342 and nuclei were counted.  Cell numbers after drug exposure were compared with numbers present on Day 0, immediately after drug was added. Calculated metrics (IC50, GI50, EC50, Hill coefficient and Einf) from this data are available in HMS-LINCS dataset 20216."	"HME1,normal,normal,breast;MDAMB231,normal,normal,breast"	"2,normal"	"GDC0941,small molecule;MK2206,small molecule;WYE125132,small molecule;Torin1,small molecule;PD0325901,small molecule"	"false:small molecules,5"	0.000166-22uM;22	3;days;1		one-all	Nuclei/cell count:kinase inhibitor sensitivity measurements	1	2015 3 31	2015 3 31						HMS - Sorger	20216: Metrics for growth responses of MDA-MB-231 and HME-1 cell lines to LINCS Phase I TransCenter Project kinase inhibitors--single drug treatments	"Analysis Dataset--This dataset presents calculated metrics (IC50, GI50, EC50, Hill coefficient and Einf) for the data in HMS-LINCS dataset #20215. The data in #20215 are measures of the sensitivities of two cell lines to the LINCS Phase I TransCenter kinase inhibitors -- cells were treated with single drugs and cell number was measured after three days of drug exposure."	"HME1,normal,normal,breast;MDAMB231,normal,normal,breast"	"2,normal"	"GDC0941,small molecule;MK2206,small molecule;WYE125132,small molecule;Torin1,small molecule;PD0325901,small molecule"	"false:small molecules,5"	0.000166-22uM;22	3;days;1		one-all	AYLSIS OF ASSAY ABOVE	1			2015 3 31					HMS - Sorger	20217:  Viability and apoptosis in BRAF(V600E/D) melanoma cell lines monitored by imaging	"Imaging assay--monitoring dose response of anti-mitotic compounds in human cancer cell lines at 24, 48, and 72 hours to determine their effects on apoptosis.  To score viability and apoptosis, a dye-based imaging assay was used; the cell-permeable D dye Hoechst 33342 was used to mark nuclei and DEVD-NucView488 caspase-3 substrate was used to mark apoptosis (stains nuclei of cells undergoing apoptosis, in which caspase 3 is active)."	"C32,normal,normal,skin;COLO858,normal,normal,skin;K2,normal,normal,skin;LOXIMVI,normal,normal,skin;MMACSF,normal,normal,skin;MZ7MEL,normal,normal,skin;RVH421,normal,normal,skin;SKMEL28,normal,normal,skin;WM115,normal,normal,skin;WM1552C,normal,normal,skin"	"10,normal"	"AZ628,small molecule;Selumetinib,small molecule;Vemurafenib,small molecule;PLX4720,small molecule;SB590885,small molecule"	"false:small molecules,5"	0.00316-3.16uM;7	"24,48,72;hrs;3"		one-all	Nuclei/cell count:image;Apoptotic cells:image	2	2015 6 30	2015 6 30	2015 6 30	2015 6 30				HMS - Sorger	20218: Phosphorylation state and protein levels measured in BRAF(V600E/D) melanoma cell lines monitored by Reverse Phase Protein Arrays (RPPA)	"Reverse Phase Protein Arrays--monitoring  phosphorylation state and protein levelsof 21 targets in BRAF(V600E/D) melanoma cell lines. Staining and analysis of RPPA data using validated antibodies were performed as described in Sevecka et al, 2011, PMID: 21296872."	"C32,normal,normal,skin;COLO858,normal,normal,skin;K2,normal,normal,skin;LOXIMVI,normal,normal,skin;MMACSF,normal,normal,skin;MZ7MEL,normal,normal,skin;RVH421,normal,normal,skin;SKMEL28,normal,normal,skin;WM115,normal,normal,skin;WM1552C,normal,normal,skin"	"10,normal"	"AZ628,small molecule;Selumetinib,small molecule;Vemurafenib,small molecule;PLX4720,small molecule;SB590885,small molecule"	"false:small molecules,5"	0.00316-3.16uM;7	"1,5,10,24,48;hrs;5"		one-all	pMEK(S217/221):phosphorylation state + protein level;pERK(T202/Y204):phosphorylation state + protein level;p-p90RSK(S380):phosphorylation state + protein level;p-p90RSK(T573):phosphorylation state + protein level;p-AKT(T308):phosphorylation state + protein level;p-AKT(S473):phosphorylation state + protein level;p-mTOR(S2448):phosphorylation state + protein level;p-p70S6K(T421/S424):phosphorylation state + protein level;p-p70S6K(T389):phosphorylation state + protein level;p-S6(S235/236):phosphorylation state + protein level;p-AMPK(T172):phosphorylation state + protein level;p-JNK(T183/Y185):phosphorylation state + protein level;Total c-Jun:phosphorylation state + protein level;p-cJun(S63):phosphorylation state + protein level;p-P38(T180/Y182):phosphorylation state + protein level;p-HSP27(S82):phosphorylation state + protein level;p-NFKB(S536):phosphorylation state + protein level;Bim:phosphorylation state + protein level;cPARP:phosphorylation state + protein level;p-Histone H3(S10):phosphorylation state + protein level;p27 Kip1:phosphorylation state + protein level	21	2015 6 30	2015 6 30	2015 6 30	2015 6 30				HMS - Sorger	20219: Phosphorylation state and protein levels measured in BRAF(V600E/D) melanoma cell lines monitored by imaging	Imaging assay--monitoring protein (or phospho protein) levels of 7 targets. 	"COLO858,normal,normal,skin;LOXIMVI,normal,normal,skin;WM115,normal,normal,skin;WM1552C,normal,normal,skin"	"4,normal"	"Vemurafenib,small molecule;JNK-IN-8,small molecule;Vemurafenib + JNK-IN-8,small molecule"	"false:small molecules,3"	0-5uM;9	24;hrs;1		one-all	p27 Kip1--Alexa488:image;p-Histone H3(S10)--Alexa488:image;Ki-67--Alexa488:image;p-Rb(S807/S811)--Alexa568:image;p-ERK(T202/Y204)--Alexa647:image;p-S6(S235/S236--Alexa647:image;p-cJun(S73)--Alexa647:image	7	2015 6 30	2015 6 30	2015 6 30	2015 6 30				HMS - Sorger	TransCenter3: Sensitivity measures of MDA-MB-231 and HME-1 cell lines to LINCS Phase I TransCenter Project kinase inhibitors - drug combinations	Imaging assay--monitoring cell number via Hoechst 33342 (nuclei) staining. To generate measures of the sensitivities of two cell lines to LINCS Phase I TransCenter Project kinase inhibitors we treated cells with two drugs at a time and measured the cell number after three days of drug exposure.  All pairwise combinations have been tested. Dataset TransCenter4 tests the same cell/drug conditions with L1000 readout.	"HME1,normal,normal,breast;MDAMB231,normal,normal,breast"	"2,normal"	"GDC0941,small molecule;MK2206,small molecule;WYE125132,small molecule;Torin1,small molecule;PD0325901,small molecule"	"false:small molecules,5"	0.000166-22uM (adjusted by drug and cell line);	3;days;1		one-all	Nuclei/cell count:kinase inhibitor sensitivity measurements	1	2015 9 30	2015 9 30						HMS - Sorger	TransCenter4: L1000 response of MDA-MB-231 and HME-1 cell lines to LINCS Phase I TransCenter Project kinase inhibitors--drug combinations	"Transcriptional response dataset-- corresponding to the cell/drug conditions tested in dataset TransCenter3, but measured with the L1000 assay at the Broad Institute."	"HME1,normal,normal,breast;MDAMB231,normal,normal,breast"	"2,normal"	"GDC0941,small molecule;MK2206,small molecule;WYE125132,small molecule;Torin1,small molecule;PD0325901,small molecule"	"false:small molecules,5"	0.000166-22uM (adjusted by drug and cell line);	"3,24;hrs;2"		one-all	L1000 gene expressions:number	1	2015 9 30	2015 9 30						HMS - Sorger	LJP5&6-L1000/single drugs: L1000 response of 6 breast cancer cell lines to treatment plates LJP5&6 (106 kinase inhibitors)	"Transcriptional response dataset-- 6 cell lines after 3 and 24 hours of treatment with 106 different kinase inhibitors at 6 different doses, measured with the L1000 assay at the Broad Institute"	"BT20,normal,cancer line,breast;HS578T,normal,cancer line,breast;MCF10A,normal,cancer line,breast;MCF7,normal,cancer line,breast;MDAMB231,normal,cancer line,breast;SKBR3,normal,cancer line,breast"	"6,normal"	"106 compounds,small molecules"	"false:small molecules,106"	"0.04uM,0.12uM,0.36uM,1.1uM,3.3uM,10uM;6"	"3,24;hrs;2"		one-all	L1000 gene expressions:number	6	2015 9 30	2015 9 30		2016 3 31				HMS - Sorger	LJP5&6-growth inhibition/single drugs: Sensitivity measures of 6 breast cancer cell lines to treatment plates LJP5&6 (106 kinase inhibitors); complement to dataset LJP5&6-L1000/single drugs.	"Imaging assay--To generate measures of the sensitivities of 6 cell lines to LJP56 plates of kinase inhibitors, we treated cells with single drugs and measured the cell number after three days of drug exposure.  "	"BT20,normal,cancer line,breast;HS578T,normal,cancer line,breast;MCF10A,normal,cancer line,breast;MCF7,normal,cancer line,breast;MDAMB231,normal,cancer line,breast;SKBR3,normal,cancer line,breast"	"6,normal"	"106 compounds,small molecules"	"false:small molecules,106"	"0.04uM,0.12uM,0.36uM,1.1uM,3.3uM,10uM;6"	"3,24;hrs;2"		one-all	Nuclei/cell count:kinase inhibitor sensitivity measurements	6	2015 9 30	2015 9 30	2015 9 30	2016 3 31				HMS - Sorger	LJP 5&6-growth inhibition/drug combinations: Sensitivity measures of 6 breast cancer cell lines to combination treatment of kinase inhibitors based on results of  dataset LJP5&6-growth inhibition/single drugs	"Imaging assay--To generate measures of the sensitivities of some cell lines to combinations of kinase inhibitors, we treated cells with drugs and measured the cell number after three days of drug exposure.  "	 among cell lines from LJP5&6-growth inhibition/ single drugs		 among HMSL compounds	"false:small molecules,"	0.01-10uM;	72;hrs;1		one-all	Nuclei/cell count:kinase inhibitor sensitivity measurements		2016 3 31	2016 3 31	2016 3 31					HMS - Sorger	LJP5&6-L1000/drug combinations: L1000 response of of 6 breast cancer cell lines to treatment plates LJP7-9 (177 targeted drugs). Complement  to dataset LJP5&6-L1000/single drugs.	"Transcriptional response dataset-- 6 cell lines after 3 and 24 hours of treatment with 177 different kinase inhibitors and chromatin modifiers at 6 different doses, measured with the L1000 assay at the Broad Institute. "	"BT20,normal,cancer line,breast;HS578T,normal,cancer line,breast;MCF10A,normal,cancer line,breast;MCF7,normal,cancer line,breast;MDAMB231,normal,cancer line,breast;SKBR3,normal,cancer line,breast"	"6,normal"	"177 compounds,small molecules"	"false:small molecules,106"	"0.04uM,0.12uM,0.36uM,1.1uM,3.3uM,10uM;6"	"3,24;hrs;2"		one-all	L1000 gene expressions:number	6	2015 12 31	2015 12 31						HMS - Sorger	Breast Cancer HCI1: High content images of 4 breast cancer cell lines treated with 106 kinase inhibitors (plates LJP5-6);collaboration with the David Andrews lab (University of Toronto)	"Imaging assay--4 cell lines treated with 3 different doses of the LJP5&6 plates of kinase inhibitors. Cells were stained with TMRE (mitochondria) and DRAQ5 (D/nuclei). Intensity, mophology and texture features were extracted at the well and single cell levels."	"BT20,normal,cancer line,breast;MCF10A,normal,cancer line,breast;MCF7,normal,cancer line,breast;MDAMB231,normal,cancer line,breast"	"4,normal"	"106 compounds,small molecules"	"false:small molecules,106"	"0.12uM,1.1uM,10uM;3"	24;hrs;1		one-all	"Intensity, mophology and texture features (300+ features total):image"	300	2015 9 30	2015 9 30						HMS - Sorger	Breast Cancer HCI2: High content images of 2 breast cancer cell lines treated with 106 kinase inhibitors (plates LJP5-6); complement to dataset Breast cancer HCI1.	"Imaging assay--2 cell lines treated with 3 different doses of the LJP5&6 plates of kinase inhibitors. Cells will be  stained with TMRE (mitochondria) and DRAQ5 (D/nuclei). Intensity, mophology and texture features will be extracted at the well and single cell levels."	"HS578T,normal,cancer line,breast;SKBR3,normal,cancer line,breast"	"2,normal"	"106 compounds,small molecules"	"false:small molecules,106"	"0.12uM,1.1uM,10uM;3"	24;hrs;1		one-all	"Intensity, mophology and texture features (300+ features total):image"	300	2015 12 31	2015 12 31						HMS - Sorger	Synovial Fibroblast 1: Secretion response of two primary human synovial fibroblast donor samples to a panel of 10 stimuli and 10 small molecule inhibitors	"Bead-based sandwich immunoassays--To generate measures of the secretion response of two primary human synovial fibroblast donor samples to individual stimulation with 10 stimuli in the presence or absence with one of 10 kinase-targeted small molecule inhibitors. Supernatant levels of 51 cytokines, chemokines, growth factors, proteases, etc are quantified. "	Human fibroblast-like synoviocytes lot #2586;Human fibroblast-like synoviocytes-RA lot #2159	"2,normal"	"CI1040,small molecule;A6730 (Sigma),small molecule;PI103,small molecule;Lestaurtinib,small molecule;Ruxolitinib,small molecule;Tofacitinib,small molecule;EO1428,small molecule;JNK-IN-8,small molecule;JNK-IN-11,small molecule;IKK16,small molecule;IL-1,protein;TNFalpha,protein;poly IC,protein"	"false:small molecules + proteins,14"	"0.1uM,3uM,0.1uM,0.3uM,0.3uM,0.3uM,1uM,3uM,0.3uM,2uM;10"	18;hrs;1		one-all	"Bioplex 27-plex and 21-plex cytokines kits (e.g. IL-6, GRO-a, MCP-1, IL-8, IP-10 and 43 other analytes) and MMP-1, -2, -3 kits from R&D Systems"	51	2015 6 30	2015 9 30	2015 12 31	2016 3 31				HMS - Sorger	"Synovial Fibroblast 2: Secretion response of seven primary human synovial fibroblast donor samples to a panel of three stimuli, five small molecule inhibitors, and one clinical-grade therapeutic antibody"	"Bead-based sandwich immunoassays--To generate measures of the secretion response landscape of seven primary human synovial fibroblast donors samples to stimulation with three stimuli in the presence or absence ot targeted inhibitors, with a key goal of evaluating variability of secretion response across patient samples. Supernatant levels of 51 cytokines, chemokines, growth factors, proteases, etc, are quantified. Indepedent experimental replicates are collected on separate days. "	"Human fibroblast-like synoviocytes lot #2586,Human fibroblast-like synoviocytes lot #2645,Human fibroblast-like synoviocytes lot #2759,Human fibroblast-like synoviocytes-RA lot #1869,Human fibroblast-like synoviocytes-RA lot 1931,Human fibroblast-like synoviocytes-RA lot #2159,Human fibroblast-like synoviocytes-RA lot #2708"	"7,normal"	"PH 797804,small molecule;JNK-IN-8,small molecule;IKK16,small molecule;Tofacitinib,small molecule;5z-7-oxozeaenol,small molecule;Tocilizumab,small molecule"	"false:small molecules + proteins,9"	"0.6uM,3uM,2uM,0.3uM,0.6uM,100ug/mL;6"	18;hrs;1		one-all	"Bioplex 27-plex and 21-plex cytokines kits (e.g. IL-6, GRO-a, MCP-1, IL-8, IP-10 and 43 other analytes) and MMP-1, -2, -3 kits from R&D Systems"	51	2015 9 30	2015 12 31	2016 3 31	2016 6 30				HMS - Sorger	"Synovial Fibroblast 3: Composition of serial dilution of RA synovial fluids, secretion response of primary human synovial fibroblasts to exposure to serial dilutions of RA synovial fluids, secretion response of primary human synovial fibroblasts to exposure to RA synovial fluids in the presence of MAP3K7/TAK1 inhibitor 5z-7-oxozeaenol"	"Bead-based sandwich immunoassays--To generate measures of (1) composition of synovial fluids from three RA patients, (2) to quantify secretion response of one primary human synovial fibroblast donor sample following individual exposure to synovial fluids from three RA patients, and (3) to quantify how this secretion response is altered by inhibition of MAP3K7/TAK1 by 5z-7-oxozeaenol. "	Human fibroblast-like synoviocytes-RA lot #2159	"1,normal"	"5z-7-oxozeaenol,small molecule;RA synovial fluid lot. no. 112050075,proteins;RA synovial fluid lot no. 113060040,proteins;RA synovial fluid lot no. 118050105,proteins;interleukin-1alpha,protein"	"false:small molecules + proteins,5"	(dose responses tested)	18;hrs;1		one-all	"Bioplex 27-plex and 21-plex cytokines kits (e.g. IL-6, GRO-a, MCP-1, IL-8, IP-10 and 43 other analytes) and MMP-1, -2, -3 kits from R&D Systems"	51	2015 12 31	2016 6 30	2016 6 30	2016 3 31	UNSURE IF QUARTERS WERE DONE PROPERLY			HMS - Sorger	BRAF4: Phosphorylation state and levels of signaling and cell state markers measured in BRAF(V600E/D) melanoma cell lines in response to drug in the presence or absence of cytokine monitored by highly multiplex (~12-plex) immunofluorescence imaging	Imaging assay--monitoring  protein (or phospho protein) levels of  multiple targets. 	"C32,normal,normal,skin;COLO858,normal,normal,skin;MMACSF,normal,normal,skin;WM115,normal,normal,skin;MZ7MEL,normal,normal,skin"	"5,normal"	"Vemurafenib,small molecule;EGF,cytokine/growth factor;PDGF,cytokine/growth factor;NRG,cytokine/growth factor;IGF,cytokine/growth factor;FGF,cytokine/growth factor;HGF,cytokine/growth factor;TGF-_,cytokine/growth factor;TNF,cytokine/growth factor"	"false:small molecules + cytokine/growth factors,9"	0-1uM;3	"24,48;hrs;1"		one-all	Phosphorylation levels of target proteins:number	>5	2016 3 31	2016 3 31						HMS - Sorger	BRAF5: Viability and apoptosis in BRAF(V600E/D) melanoma cell lines  in response to drug in the presence or absence of cytokine monitored by imaging	"Imaging assay--monitoring dose response of anti-mitotic compounds in human cancer cell lines at 72 to 96 hours to determine their effects on apoptosis.  To score viability and apoptosis, a dye-based imaging assay will be used; the cell-permeable D dye Hoechst 33342 is used to mark nuclei and DEVD-NucView488 caspase-3 substrate is used to mark apoptosis (stains nuclei of cells undergoing apoptosis, in which caspase 3 is active)."	"C32,normal,normal,skin;COLO858,normal,normal,skin;MMACSF,normal,normal,skin;WM115,normal,normal,skin;MZ7MEL,normal,normal,skin"	"5,normal"	"Vemurafenib,small molecule;EGF,cytokine/growth factor;PDGF,cytokine/growth factor;NRG,cytokine/growth factor;IGF,cytokine/growth factor;FGF,cytokine/growth factor;HGF,cytokine/growth factor;TGF-_,cytokine/growth factor;TNF,cytokine/growth factor"	"false:small molecules + cytokine/growth factors,9"	0-1uM;4	"72,96;hrs;1"		one-all	Nuclei/cell count:image;Apoptotic cells:image	2	2016 3 31	2016 3 31						HMS - Sorger	BRAF6: Phosphorylation state and levels of ~24 transcription factors measured in BRAF(V600E/D) melanoma cell lines monitored by imaging	Imaging assay--monitoring  protein (or phospho protein) levels of  multiple targets.	"COLO858,normal,normal,skin;WM115,normal,normal,skin;MMACSF,normal,normal,skin;MZ7MEL,normal,normal,skin"	"4,normal"	"Vemurafenib,small molecule"	"false:small molecules,1"	0-1uM;5	48;hrs;1		one-all	Phosphorylation levels of target proteins:number	>5	2016 3 31	2016 3 31						HMS - Sorger	MassSpecPhos1: Basal profiling of phosphoproteins measured by mass spec	Mass Spec assay--Basal profiling of the phosphoproteins. Cells will be serum starved for 24 hours before sample collection. 	"BT20,normal,cancer line,breast;HS578T,normal,cancer line,breast;MCF10A,normal,cancer line,breast;MCF7,normal,cancer line,breast;MDAMB231,normal,cancer line,breast;SKBR3,normal,cancer line,breast"	"6,normal"		"false:,"				one-all	mass spec		2016 3 31	2016 3 31																										Broad - Jaffe	P100	Reduced Representation Phosphoprofiling	"MCF7,normal,cancer line,breast;PC3,normal,cancer line,prostate;A549,normal,cancer line,lung;A375,normal,cancer line,skin;,normal,cancer line,pancreas;NPC,normal,differentiated line,brain"	"6,normal"	" tranche2,chemical;1271738-62-5 (MI-2),chemical;acetyldinaline (Ci-994),chemical;belinostat,chemical;BIX 01294,chemical;CPI-169,chemical;decitabine,chemical;DMSO,chemical;entinostat (MS275),chemical;EPZ-5676,chemical;EPZ-5687,chemical;EPZ004777,chemical;EX527,chemical;geldanamycin,chemical;GSK-J4,chemical;GSK1210151A,chemical;gsk126,chemical;GSK525762A,chemical;jq1,chemical;LY-294002,chemical;methylstat,chemical;OSI-027,chemical;rapamycin,chemical;resveratrol,chemical;salermide,chemical;staurosporine,chemical;trichostatin-a,chemical;UNC0321,chemical;UNC0646,chemical;UNC1215,chemical;vorinostat,chemical;zebularine,chemical"	"false:chemical,32"	;1	3;hrs;1	3	one-all	:number matrix	100	2015 6 30	2015 6 30	2015 6 30	2015 6 30				Broad - Jaffe	GCP	Global Chromatin Profiling	"MCF7,normal,cancer line,breast;PC3,normal,cancer line,prostate;A549,normal,cancer line,lung;A375,normal,cancer line,skin;,normal,cancer line,pancreas;NPC,normal,differentiated line,brain"	"6,normal"	" tranche2,chemical;1271738-62-5 (MI-2),chemical;acetyldinaline (Ci-994),chemical;belinostat,chemical;BIX 01294,chemical;CPI-169,chemical;decitabine,chemical;DMSO,chemical;entinostat (MS275),chemical;EPZ-5676,chemical;EPZ-5687,chemical;EPZ004777,chemical;EX527,chemical;geldanamycin,chemical;GSK-J4,chemical;GSK1210151A,chemical;gsk126,chemical;GSK525762A,chemical;jq1,chemical;LY-294002,chemical;methylstat,chemical;OSI-027,chemical;rapamycin,chemical;resveratrol,chemical;salermide,chemical;staurosporine,chemical;trichostatin-a,chemical;UNC0321,chemical;UNC0646,chemical;UNC1215,chemical;vorinostat,chemical;zebularine,chemical"	"false:chemical,32"	;1	24;hrs;1	3	one-all	:number matrix	100	2015 6 30	2015 6 30	2015 6 30	2015 6 30	DIFFERENT RELEASE DATES FOR DIFFERENT PERTURBAGENS																							UCIrvine - Thompson	iMN toxicity as determined by RM	"Imaging assay--monitoring cell survival in control, ALS, and SMA iMNs. iMNs will be transfected with a fluorescence reporter and imaged daily for 10 days. Images will be run through a custom analysis software package that tracks individual cells over time. The time of death (if it occurs) for each neuron will be determined. Neurite arborization will be determined using custom software analysis on these images. ."	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain"	"12,ips-differentiated"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease"	"false:diseases,2"		"24,48,72,96,120,144;hrs;6"	2	"control,CS00iCTR-n2;control,CS14iCTR-n6;control,CS83iCTR-33n1;control,CS25iCTR-18n2;amyotrophic lateral sclerosis,CS28iALS-n2A;amyotrophic lateral sclerosis,CS29iALS-n1N;amyotrophic lateral sclerosis,CS30iALS-n1A;amyotrophic lateral sclerosis,CS52iALS-n6A;spinal muscular atrophy,CS32iSMA-n3;spinal muscular atrophy,CS13iSMA-n1;spinal muscular atrophy,83iSMA-n5;spinal muscular atrophy,CS77iSMA-n5"	cell fluorescence:image;survival time:image;morphology:image	3	2015 6 30	2015 9 30	2015 12 31					UCIrvine - Thompson	iMN glutamate toxicity- Excitotoxicity	"iPSN Sensitivity to Glutamate-induced Toxicity. To test iPSN sensitivity to glutamate-induced excitotoxicity,  control and ALS/SMA iPSNs will be treated with various concentrations of L-glutamate (1, 3, 10, 30, 100 uM) for 2 to 8 hr in NDM, all concentrations for each experiment will be performed in triplicate. At the appropriate time point, cells will be incubated with 1 uM propidium iodide and 1 uM calcein AM for 30 min to visualize dead and live cells, respectively.  Five to ten fields of view will then be imaged for each treatment using excitation/emission filters of 535/617 nm and 495/515 nm for propidium iodide and calcein AM, respectively. The number of propidium iodide positive and calcein AM iPSNs will be quantified using Image J over 3 separate experiments. "	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain"	"12,ips-differentiated"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease;L-glutamate,small molecule"	"false:diseases,2;small molecules,1"	"1uM,3uM,10uM,30uM,100uM;5"	"2,4,6,8;hrs;4"	2	"control,CS00iCTR-n2;control,CS14iCTR-n6;control,CS83iCTR-33n1;control,CS25iCTR-18n2;amyotrophic lateral sclerosis,CS28iALS-n2A;amyotrophic lateral sclerosis,CS29iALS-n1N;amyotrophic lateral sclerosis,CS30iALS-n1A;amyotrophic lateral sclerosis,CS52iALS-n6A;spinal muscular atrophy,CS32iSMA-n3;spinal muscular atrophy,CS13iSMA-n1;spinal muscular atrophy,83iSMA-n5;spinal muscular atrophy,CS77iSMA-n5;glutamate,CS00iCTR-n2;glutamate,CS14iCTR-n6;glutamate,CS83iCTR-33n1;glutamate,CS25iCTR-18n2;glutamate,CS28iALS-n2A;glutamate,CS29iALS-n1N;glutamate,CS30iALS-n1A;glutamate,CS52iALS-n6A;glutamate,CS32iSMA-n3;glutamate,CS13iSMA-n1;glutamate,83iSMA-n5;glutamate,CS77iSMA-n5"	cell fluorescence after propidium iodide:image;number of cells with PI uptake:image features	2	2015 6 30	2015 9 30	2015 12 31					UCIrvine - Thompson	iMN Tunicamycin Toxicity: ER Stress	"Sensitivity to tunicamycin/ER Stress.  iPS neurons will be  differentiated in 24 well plates for 39 days before treatment with increasing tunicamycin concentrations (0, 0.1, 0.3, 0.6, 1.0, or 3.0 uM). After 24 h of incubation with tunicamycin, 0.5 uM of propidium iodide (PI) will be added to each well and incubated for 30 minutes. The PI signal will be imaged. For each treatment and dose, at least 10 images were taken per experiment, and the number of iPS neurons exhibiting PI uptake will be quantified using the analyze particle function of the Image J software (NIH)."	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain"	"12,ips-differentiated"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease;tunicamycin,small molecule"	"false:diseases,2;small molecules,1"	"0uM,0.1uM,0.3uM,0.6uM,1uM,3uM;6"	24;hrs;1	2	"control,CS00iCTR-n2;control,CS14iCTR-n6;control,CS83iCTR-33n1;control,CS25iCTR-18n2;amyotrophic lateral sclerosis,CS28iALS-n2A;amyotrophic lateral sclerosis,CS29iALS-n1N;amyotrophic lateral sclerosis,CS30iALS-n1A;amyotrophic lateral sclerosis,CS52iALS-n6A;spinal muscular atrophy,CS32iSMA-n3;spinal muscular atrophy,CS13iSMA-n1;spinal muscular atrophy,83iSMA-n5;spinal muscular atrophy,CS77iSMA-n5;tunicamycin,CS00iCTR-n2;tunicamycin,CS14iCTR-n6;tunicamycin,CS83iCTR-33n1;tunicamycin,CS25iCTR-18n2;tunicamycin,CS28iALS-n2A;tunicamycin,CS29iALS-n1N;tunicamycin,CS30iALS-n1A;tunicamycin,CS52iALS-n6A;tunicamycin,CS32iSMA-n3;tunicamycin,CS13iSMA-n1;tunicamycin,83iSMA-n5;tunicamycin,CS77iSMA-n5"	cell fluorescence after propidium iodide:image;number of cells with PI uptake:image features	3	2015 6 30	2015 9 30	2015 12 31					UCIrvine - Thompson	Baseline Rseq for control and diseased iPSC lines	"Baseline gene expression dataset for QC and pipeline development -- 11 total control iPSC cell lines 3 in triplicate and 1 in duplicate and 28 diseased iPSC, 4 ALS and 4 SMA with replicates and with no additional perturbagen. Determine cell line variability and assay reproducibility. Rseq QC statistics and expression correlation statistics will guide the development of QC statndards and appropriate analysis pipeline."		"39,ips-differentiated"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease"	"false:diseases,2"					gene expression:number	1	2015 6 30	2015 9 30	2015 12 31					UCIrvine - Thompson	Rseq for control and diseased iMNs	"Baseline gene expression dataset for iMN and diseased state signature -- 4 control, 4 ALS, and 4 SMA iPSC-derived iMN with replicates and with no additional perturbagen. Generate gene expression signatures and analyze disease/control contrast for statistically significant differentially expressed genes. Generate disease signatures for future systems analysis: pathway, network, and category enrichment analysis, as well as for integration with other omics and machine learning analyses. "	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain"	"12,ips-differentiated"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease"	"false:diseases,2"					gene expression:number	1	2015 6 30	2015 9 30	2015 12 31					UCIrvine - Thompson	Rseq for control and diseased iMNs plus perturbations	"Gene expression dataset for iMN and disease signature reponse to perturbagens -- 4 control, 4 ALS, and 4 SMA iPSC-derived iMN with replicates plus additional perturbagen. Generate gene expression signatures and for both disease and control and analyze perturb/disease & perturb/control contrasts for statistically significant differentially expressed genes. Using a GLM setup multi-factor design matrix to analyze disease vs control with each perturbagen as an additional factor. Generate signatures for future systems analysis: pathway, network, and category enrichment analysis, as well as for integration with other omics and machine learning analyses. "	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain"		"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease;,small molecule"	"false:diseases,2;stimulation,"					gene expression:number	1	2015 6 30	2015 9 30	2015 12 31					UCIrvine - Thompson	QC and SOP development for proteomic analysis  iPSC to  motor neuron differentiation	"MS analysis on the QE and or Triple TOF MS instrument  of trypsin digested  iPSC dervied from 4 control, 4 ALS and 4 SMA lines for 3 different wells at  multiple cell passages."	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain"	"12,ips-differentiated"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease"	"false:diseases,2"					protein levels:number	1	2015 6 30	2015 9 30						UCIrvine - Thompson	"Quantitative discovery proteomics (SWATH), compare iPSC and mature differentitated neurons"	"Build MS SWATH data library: using  the QE and 6600 MS instrument analyzing either fractionated individuals and pools of iPSC dervied from  4 controls and SMA and ALS lines into soluble, insoluble and acid soluble."	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain"	"12,ips-differentiated;12,mature motor neurons"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease"	"false:diseases,2"					protein levels:number	1	2015 6 30	2015 9 30	2015 12 31					UCIrvine - Thompson	"Quantitative discovery proteomics (SWATH), compare iPSC, neural rosettes and differentated neurons"	"Build MS SWATH data library: using  the 6600 MS instrument analyzing either fractionated individuals and  pools of iPSC dervied from  4 controls and SMA and ALS lines into soluble, insoluble and acid soluble enriched for phosphorylation."	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS00iCTR-n2,mature motor neuron,normal:control,brain;CS14iCTR-n6,mature motor neuron,spinal muscular atrophy:control,brain;CS83iCTR-33n1,mature motor neuron,huntington's disease:control,brain;CS25iCTR-18n2,mature motor neuron,huntington's disease:control,brain;CS28iALS-n2A,mature motor neuron,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,mature motor neuron,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,mature motor neuron,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,mature motor neuron,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,mature motor neuron,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,mature motor neuron,spinal muscular atrophy:diseased,brain;83iSMA-n5,mature motor neuron,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,mature motor neuron,spinal muscular atrophy:diseased,brain;CS00iCTR-n2,ips-differentiated-phosphorylation enriched,normal:control,brain;CS14iCTR-n6,ips-differentiated-phosphorylation enriched,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated-phosphorylation enriched,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated-phosphorylation enriched,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated-phosphorylation enriched,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated-phosphorylation enriched,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated-phosphorylation enriched,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated-phosphorylation enriched,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated-phosphorylation enriched,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated-phosphorylation enriched,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated-phosphorylation enriched,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated-phosphorylation enriched,spinal muscular atrophy:diseased,brain;CS00iCTR-n2,mature motor neuron-phosphorylation,normal:control,brain;CS14iCTR-n6,mature motor neuron-phosphorylation,spinal muscular atrophy:control,brain;CS83iCTR-33n1,mature motor neuron-phosphorylation,huntington's disease:control,brain;CS25iCTR-18n2,mature motor neuron-phosphorylation,huntington's disease:control,brain;CS28iALS-n2A,mature motor neuron-phosphorylation,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,mature motor neuron-phosphorylation,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,mature motor neuron-phosphorylation,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,mature motor neuron-phosphorylation,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,mature motor neuron-phosphorylation,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,mature motor neuron-phosphorylation,spinal muscular atrophy:diseased,brain;83iSMA-n5,mature motor neuron-phosphorylation,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,mature motor neuron-phosphorylation,spinal muscular atrophy:diseased,brain"	"12,ips-differentiated;12,mature motor neurons"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease"	"false:diseases,2"					protein levels:number	1	2015 6 30	2015 9 30	2015 12 31					UCIrvine - Thompson	"Quantitative discovery proteomics (SWATH), add perturbagens"	Various perturbations on IPSC and potentially neurons. Analyze total protein and phosphorylation initially	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS00iCTR-n2,mature motor neuron,normal:control,brain;CS14iCTR-n6,mature motor neuron,spinal muscular atrophy:control,brain;CS83iCTR-33n1,mature motor neuron,huntington's disease:control,brain;CS25iCTR-18n2,mature motor neuron,huntington's disease:control,brain;CS28iALS-n2A,mature motor neuron,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,mature motor neuron,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,mature motor neuron,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,mature motor neuron,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,mature motor neuron,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,mature motor neuron,spinal muscular atrophy:diseased,brain;83iSMA-n5,mature motor neuron,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,mature motor neuron,spinal muscular atrophy:diseased,brain;CS00iCTR-n2,ips-differentiated-phosphorylation enriched,normal:control,brain;CS14iCTR-n6,ips-differentiated-phosphorylation enriched,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated-phosphorylation enriched,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated-phosphorylation enriched,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated-phosphorylation enriched,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated-phosphorylation enriched,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated-phosphorylation enriched,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated-phosphorylation enriched,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated-phosphorylation enriched,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated-phosphorylation enriched,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated-phosphorylation enriched,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated-phosphorylation enriched,spinal muscular atrophy:diseased,brain;CS00iCTR-n2,mature motor neuron-phosphorylation,normal:control,brain;CS14iCTR-n6,mature motor neuron-phosphorylation,spinal muscular atrophy:control,brain;CS83iCTR-33n1,mature motor neuron-phosphorylation,huntington's disease:control,brain;CS25iCTR-18n2,mature motor neuron-phosphorylation,huntington's disease:control,brain;CS28iALS-n2A,mature motor neuron-phosphorylation,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,mature motor neuron-phosphorylation,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,mature motor neuron-phosphorylation,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,mature motor neuron-phosphorylation,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,mature motor neuron-phosphorylation,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,mature motor neuron-phosphorylation,spinal muscular atrophy:diseased,brain;83iSMA-n5,mature motor neuron-phosphorylation,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,mature motor neuron-phosphorylation,spinal muscular atrophy:diseased,brain"	"12,ips-differentiated;12,mature motor neurons"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease;stimulation A-N,stimulation"	"false:diseases,2;stimulation A-N,2"					protein levels:number	1	2015 6 30	2015 9 30	2015 12 31					UCIrvine - Thompson	Epigenomics - Baseline ATAC-Seq for control and disease iPSC lines	"Baseline ATAC-seq experiments for protocol assay optimization, QC and development of analysis methods -- 4 control, 4 ALS and 4 SMA iPSC cell lines with replicates, without additional perturbagens. Determine optimal conditions for purification of high quality nuclei to preserve chromatin structure and for transposase reaction (number of nuclei, enzyme concentration and incubation time) to avoid over- or under-digestion. Set up analysis pipelines and perform correlation and clustering tests to determine cell line variability and assay reproducibility  between either technical or biological replicates and Identify potential problematic samples."	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain"	"12,ips-differentiated"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease"	"false:diseases,2"			3		Raw Data (fastq) and BAM files (aligned reads):sequence;Genomic coordinates and intensity for each significant peak:number;Differentially expressed peaks relative to population control:number	3	2015 6 30	2015 9 30	2015 12 31					UCIrvine - Thompson	Epigenomics - ATAC-Seq for control and disease iMNs	"Baseline ATAC-seq experiments for iMN and disease state signatures -- 4 control, 4 ALS, and 4 SMA iPSC-derived iMN lines with replicates without additional perturbagens. Annotate open chromatin regions and map transcription factor binding events in regulatory elements genome-wide. Generate chromatin accessibility signatures  for each sample individually by calculating the enrichment of genomic regions relative to a set of control reads from Tn5-treated naked genomic D. Detect differential peaks between disease and control state. Generate disease signatures for future systems analysis and integration with other omics by 1) identifying genes mapping near differential peaks and detecting significantly enriched GO terms for these gene lists; 2) performing D foorprinting, motif scoring and applying regression methods to infer transcription factors responsible for gene expression signatures."	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain"	"12,ips-differentiated"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease"	"false:diseases,2"			3		Raw Data (fastq) and BAM files (aligned reads):sequence;Genomic coordinates and intensity for each significant peak:number;Differentially expressed peaks relative to population control:number	3	2015 6 30	2015 9 30	2015 12 31					UCIrvine - Thompson	Epigenomics - ATAC-Seq for control and disease iMNs plus perturbations	"ATAC-seq dataset for iMN and disease signature reponse to perturbagens -- 4 control, 4 ALS, and 4 SMA iPSC-derived iMN lines with replicates plus additional perturbagens. Generate chromatin accessibility signatures  for each sample individually by calculating the enrichment of genomic regions relative to a set of control reads from Tn5-treated naked genomic D. Analyze perturb/disease & perturb/control datasets to detecte differentially enriched peaks reflecting changes in chromatin structures as a consequence of perturbation. Generate disease signatures for future systems analysis and integration with other omics and machine learning analyses."	"CS00iCTR-n2,ips-differentiated,normal:control,brain;CS14iCTR-n6,ips-differentiated,spinal muscular atrophy:control,brain;CS83iCTR-33n1,ips-differentiated,huntington's disease:control,brain;CS25iCTR-18n2,ips-differentiated,huntington's disease:control,brain;CS28iALS-n2A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS29iALS-n1N,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS30iALS-n1A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS52iALS-n6A,ips-differentiated,amyotrophic lateral sclerosis:diseased,brain;CS32iSMA-n3,ips-differentiated,spinal muscular atrophy:diseased,brain;CS13iSMA-n1,ips-differentiated,spinal muscular atrophy:diseased,brain;83iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain;CS77iSMA-n5,ips-differentiated,spinal muscular atrophy:diseased,brain"	"12,ips-differentiated"	"spinal muscular atrophy,disease;amyotrophic lateral sclerosis,disease"	"false:diseases,2"			3		Raw Data (fastq) and BAM files (aligned reads):sequence;Genomic coordinates and intensity for each significant peak:number;Differentially expressed peaks relative to population control:number	3	2015 6 30	2015 9 30	2015 12 31																									OHSU - Gray	High-throughput MEMA array	Use microenvironment microarray (MEMA) based platform to assess the impacts of ~3000 different pairwise combinations of ME perturbagens (MEPs) on 10 biological response endopoints.	"MCF7,normal,cancer line,breast;HPAC,normal,cancer line,pancreas;PC3,normal,cancer line,prostate"	"3,normal"	"Collagen I,ECM;Collagen I,ECM;Collagen Type II,ECM;Collagen Type III,ECM;Collagen Type IV,ECM;Collagen Type IV,ECM;Collagen Type V,ECM;Collagen XXIII _1/COL23A1,ECM;Desmoglein 2,ECM;E-cadherin Fc Chimera,ECM;ECM1,ECM;Fibronectin 1,ECM;GAP43,ECM;HyA-500K,ECM;HyA-50K,ECM;ICAM-1,ECM;Integrin _10_1,ECM;Integrin _11_1,ECM;Integrin _2_1,ECM;Integrin _3_1,ECM;Integrin _4_1,ECM;Integrin _6_4,ECM;Integrin _9_1,ECM;Integrin _M_2,ECM;Integrin _V_6,ECM;ITGAM-B2,ECM;laminin,ECM;Laminin-1,ECM;Laminin-5,ECM;Lumican,ECM;M-Cadherin/Cadherin-15 Fc Chimera,ECM;Osteoadherin,ECM;Osteopontin,ECM;P-Cadherin Fc Chimera,ECM;PECAM1,ECM;RGD-cyclic,ECM;rhNidogen-1,ECM;Tenascin C,ECM;VCAM1,ECM;vitronectin,ECM;ALCAM,ECM;Cadherin-20 (CAD-20),ECM;Cadherin-6/KCAD Fc Chimera,ECM;rhCadherin-8 (CAD-8)/FC Chimera,ECM;CD44,ECM;CEACAM6,ECM;ANGPT1,Growth Factor;ANGPT2,Growth Factor;AREG (amphiregulin),Growth Factor;CI-4AS-1,Growth Factor;CTGF,Growth Factor;CXCL12/SDF1a,Growth Factor;CXCL12/SDF1b aa 22-93,Growth Factor;DLL1,Growth Factor;DLL4,Growth Factor;EGF,Growth Factor;B-estradiol,Growth Factor;Fas Ligand/TNFSF6,Growth Factor;Fetuin A/AHSG,Growth Factor;FGF basic 146 aa,Growth Factor;FGF2,Growth Factor;FGF6,Growth Factor;FLT3,Growth Factor;GM-CSF,Growth Factor;Gro-a,Growth Factor;HGF,Growth Factor;IGF-1,Growth Factor;IGFBP2,Growth Factor;IGFBP3,Growth Factor;IL-7,Growth Factor;CXCL8/IL-8,Growth Factor;IL-13,Growth Factor;IL-15,Growth Factor;IL-6,Growth Factor;Interleukin-1 beta (IL-1_) [catabolin],Growth Factor;Jagged 1 Fc Chimera,Growth Factor;Jagged 2,Growth Factor;Kininogen High Molecular Weight,Growth Factor;LECT2,Growth Factor;Leptin/OB,Growth Factor;LYVE-1,Growth Factor;a-HRG,Growth Factor;NRG1-_1/HRG1-_1 EGF domain,Growth Factor;Osteoprotegerin/TNFRSF11B,Growth Factor;Osteoactivin/GPNMB Fc Chimera,Growth Factor;PDGF-AB,Growth Factor;PDGF-BB,Growth Factor;Podoplanin,Growth Factor;Progesterone ,Growth Factor;PTN (pleiotropin),Growth Factor;rhBMP-2,Growth Factor;rhBMP-3,Growth Factor;rhBMP-4,Growth Factor;rhBMP-5,Growth Factor;rhBMP-6,Growth Factor;rhBMP-7,Growth Factor;rhTRANCE,Growth Factor;SCF/c-kit ligand,Growth Factor;SHH,Growth Factor;SMDF-HRG,Growth Factor;TGF-_ Latency Associated Protein,Growth Factor;TGF-B1,Growth Factor;TGF-B2,Growth Factor;TNFa,Growth Factor;Thrombopoietin/Tpo,Growth Factor;VEGF 165,Growth Factor;WNT3a,Growth Factor;WNT5a,Growth Factor;WNT10a,Growth Factor"	"true:pairwise MEPs,3000"			6	one-all	"Quantitated image features, antibody sets 1,2,3:image features"	13	2015 6 1	2015 6 1	2015 6 1	2015 6 1				OHSU - Gray	High-throughput MEMA array	Use microenvironment microarray (MEMA) based platform to assess the impacts of ~3000 different pairwise combinations of ME perturbagens (MEPs) on 10 biological response endopoints.	"HCC1954,normal,cancer line,breast;A549,normal,cancer line,lung;A375,normal,cancer line,skin"	"3,normal"	"Collagen I,ECM;Collagen I,ECM;Collagen Type II,ECM;Collagen Type III,ECM;Collagen Type IV,ECM;Collagen Type IV,ECM;Collagen Type V,ECM;Collagen XXIII _1/COL23A1,ECM;Desmoglein 2,ECM;E-cadherin Fc Chimera,ECM;ECM1,ECM;Fibronectin 1,ECM;GAP43,ECM;HyA-500K,ECM;HyA-50K,ECM;ICAM-1,ECM;Integrin _10_1,ECM;Integrin _11_1,ECM;Integrin _2_1,ECM;Integrin _3_1,ECM;Integrin _4_1,ECM;Integrin _6_4,ECM;Integrin _9_1,ECM;Integrin _M_2,ECM;Integrin _V_6,ECM;ITGAM-B2,ECM;laminin,ECM;Laminin-1,ECM;Laminin-5,ECM;Lumican,ECM;M-Cadherin/Cadherin-15 Fc Chimera,ECM;Osteoadherin,ECM;Osteopontin,ECM;P-Cadherin Fc Chimera,ECM;PECAM1,ECM;RGD-cyclic,ECM;rhNidogen-1,ECM;Tenascin C,ECM;VCAM1,ECM;vitronectin,ECM;ALCAM,ECM;Cadherin-20 (CAD-20),ECM;Cadherin-6/KCAD Fc Chimera,ECM;rhCadherin-8 (CAD-8)/FC Chimera,ECM;CD44,ECM;CEACAM6,ECM;ANGPT1,Growth Factor;ANGPT2,Growth Factor;AREG (amphiregulin),Growth Factor;CI-4AS-1,Growth Factor;CTGF,Growth Factor;CXCL12/SDF1a,Growth Factor;CXCL12/SDF1b aa 22-93,Growth Factor;DLL1,Growth Factor;DLL4,Growth Factor;EGF,Growth Factor;B-estradiol,Growth Factor;Fas Ligand/TNFSF6,Growth Factor;Fetuin A/AHSG,Growth Factor;FGF basic 146 aa,Growth Factor;FGF2,Growth Factor;FGF6,Growth Factor;FLT3,Growth Factor;GM-CSF,Growth Factor;Gro-a,Growth Factor;HGF,Growth Factor;IGF-1,Growth Factor;IGFBP2,Growth Factor;IGFBP3,Growth Factor;IL-7,Growth Factor;CXCL8/IL-8,Growth Factor;IL-13,Growth Factor;IL-15,Growth Factor;IL-6,Growth Factor;Interleukin-1 beta (IL-1_) [catabolin],Growth Factor;Jagged 1 Fc Chimera,Growth Factor;Jagged 2,Growth Factor;Kininogen High Molecular Weight,Growth Factor;LECT2,Growth Factor;Leptin/OB,Growth Factor;LYVE-1,Growth Factor;a-HRG,Growth Factor;NRG1-_1/HRG1-_1 EGF domain,Growth Factor;Osteoprotegerin/TNFRSF11B,Growth Factor;Osteoactivin/GPNMB Fc Chimera,Growth Factor;PDGF-AB,Growth Factor;PDGF-BB,Growth Factor;Podoplanin,Growth Factor;Progesterone ,Growth Factor;PTN (pleiotropin),Growth Factor;rhBMP-2,Growth Factor;rhBMP-3,Growth Factor;rhBMP-4,Growth Factor;rhBMP-5,Growth Factor;rhBMP-6,Growth Factor;rhBMP-7,Growth Factor;rhTRANCE,Growth Factor;SCF/c-kit ligand,Growth Factor;SHH,Growth Factor;SMDF-HRG,Growth Factor;TGF-_ Latency Associated Protein,Growth Factor;TGF-B1,Growth Factor;TGF-B2,Growth Factor;TNFa,Growth Factor;Thrombopoietin/Tpo,Growth Factor;VEGF 165,Growth Factor;WNT3a,Growth Factor;WNT5a,Growth Factor;WNT10a,Growth Factor"	"true:pairwise MEPs,3000"			6	one-all	"Quantitated image features, antibody sets 1,2,3:image features"	13	2015 12 1	2015 12 1	2015 12 1	2015 12 1				